menu
    • menu
    [{"orgOrder":0,"company":"Horus Pharma","sponsor":"Horus Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase I","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Horus Pharma \/ Horus Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Horus Pharma \/ Horus Pharma"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Horus Pharma \/ Alimera Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Horus Pharma \/ Alimera Sciences"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Horus Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Barcimiant","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Horus Pharma \/ Horus Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Horus Pharma \/ Horus Pharma"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"Aflibercept","moa":"VEGF-A | PlGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horus Pharma \/ Horus Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Horus Pharma \/ Horus Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Horus Pharma

    Menu

    Horus Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : Formycon

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Horus Pharma Becomes Additional Commercialization Partner for Formycon's Eylea Biosimilar

                            Details : The partnership aims for the commercialization of Formycon's Eylea biosimilar FYB203, under the brand name Baiama, in selected European countries.

                            Product Name : Baiama

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            September 17, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : Formycon

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Alimera Sciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN®...

                            Details : Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Euro...

                            Product Name : Iluvien

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            April 03, 2023

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Alimera Sciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barcimiant

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumian...

                            Details : Barcimiant is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : Barcimiant

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed

                            Horus Pharma

                            France arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt...

                            Details : Rivaroxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2017

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth